Phathom Pharmaceuticals, Inc.
NASDAQ:PHATBiotechnology
-$0.27 today
- Market cap
- $430.84M
- Beta
- 0.51
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$1.92
Volume 1.67M
Average 1.21M
PHAT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Phathom Pharmaceuticals, Inc.NASDAQ: PHAT
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities remains negative
Q1 FY2026 other current liabilities was $118.01M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +146.4% a year.
Context
- Other current liabilities amounted to 38.7% of total assets at the end of Q1 FY2026, up 38.7 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 126.41M USD
- Year-over-year change
- +130.1%
- 4-year CAGR
- +111.3%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 126.41M | +130.1% |
| FY2024 | 2024-12-31 | 54.94M | +168.9% |
| FY2023 | 2023-12-31 | 20.43M | +141.8% |
| FY2022 | 2022-12-31 | 8.45M | +33.1% |
| FY2021 | 2021-12-31 | 6.34M | — |
Other Current Liabilities vs competitors
How PHAT compares with its peers on the latest reported figures
- PHAT's Mar 2026 other current liabilities of $118.01M is the highest of the 2 companies compared; the peer median is $9.38M.
- Other current liabilities amounts to 38.7% of total assets for PHAT, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $118.01M | — | +146.4% | 38.7% | |
| Mar 2026 | $9.38M | +30.9% | +87.7% | 1.9% | |
| Peer median (excluding PHAT) | $9.38M | +30.9% | +87.7% | 1.9% | |
Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 183.26M | 155.39M | 381.39M | 297.26M | 129.97M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 1.64M | 38.8M | 78.13M |
| Inventory | 0 | 0 | 1.21M | 3.21M | 5.52M |
| Other Current Assets | 3.27M | 5.13M | 13.19M | 20.87M | 15.35M |
| Total Current Assets | 186.53M | 160.51M | 397.43M | 360.13M | 228.97M |
| Property, Plant & Equipment (Net) | 2.56M | 3.49M | 3.62M | 2.09M | 3.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 505K | 0 | 2.86M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 341K | 299K | 12.79M | 13.23M | 26.51M |
| Total Non-current Assets | 2.91M | 4.3M | 16.41M | 18.18M | 30.18M |
| Total Assets | 189.43M | 164.81M | 413.84M | 378.32M | 259.15M |
| Account Payables | 5.15M | 10M | 12.6M | 10.51M | 4.98M |
| Short-term Debt | 0 | 0 | 0 | 19.78M | 648K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.34M | 8.45M | 20.43M | 54.94M | 126.41M |
| Total Current Liabilities | 18.92M | 26.24M | 38.78M | 85.73M | 132.04M |
| Long-term Debt | 89.67M | 95.26M | 137.84M | 534.67M | 209.09M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.5M | 117.03M | 309.52M | 11.5M | 354.12M |
| Total Non-current Liabilities | 98.35M | 213.39M | 447.82M | 546.17M | 565.27M |
| Total Liabilities | 117.28M | 239.62M | 486.6M | 631.9M | 697.32M |
| Common Stock | 3K | 3K | 5K | 6K | 6K |
| Retained Earnings | (529.37M) | (727.09M) | (928.69M) | (1.26B) | (1.48B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 72.16M | (74.81M) | (72.76M) | (253.58M) | (438.17M) |
| Total Debt | 91.34M | 97.07M | 139.03M | 554.95M | 211.8M |
| Net Debt | (91.92M) | (58.32M) | (242.36M) | 257.68M | 81.83M |
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
Intrinsic Alpha fair value
Locked
Current Price
$5.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.